Physician profile
Lee M Glickman
NPI 1295702884
$35,062.64
in general payments reported to CMS, 2019-2025
20 companies · $21.64 in 2025
The $21.64 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,346 · 2021: $14K · 2022: $4,653 · 2023: $1,237 · 2024: $361 · 2025: $21.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587 · Education: $32.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.97 |
| Education | $32.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30,668.43 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $1,475.64 | 2019 | |
| Merck Sharp & Dohme LLC | $534.73 | 2021-2024 | Verquvo |
| Amgen INC. | $463.79 | 2021-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $441.47 | 2021-2024 | |
| Boston Scientific Corporation | $355.03 | 2019-2024 | Watchman Flx, Vigilant X4 Crt-D, Watchman Access System |
| Abbott Laboratories | $331.26 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $138.50 | 2022 | |
| Pfizer INC. | $96.95 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $92.32 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.12 | 2019-2023 | Lifevest |
| Alnylam Pharmaceuticals INC. | $81.06 | 2023 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $69.81 | 2022-2023 | Farxiga |
| Altathera Pharmaceuticals LLC | $52.20 | 2022-2023 | Sotalol Hydrochloride |
| Kestra Medical Technology Services, INC. | $39.91 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.44 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $30.82 | 2021-2023 | |
| Preventice Services, LLC | $30.47 | 2021 | |
| Edwards Lifesciences Corporation | $21.64 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $19.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Glickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.